Disease
Liver transplantation肝移植
ICD-10: Z94 — Liver transplant status
National medical service item code: 013317000020000 — Liver transplantation 肝脏移植术
Key figures
Published values only. Every tile opens the section that carries its source, its year and its caliber.
Disease details
- Standard Chinese name
- Liver transplant 肝移植
- English name
- Liver transplant status
Values written in Chinese are quoted as published by the source.
Also known as
- Liver transplantation
- Liver transplant
Treatment cost ranges
| Treatment path | Cost range | Caliber | Price basis | Data year |
|---|---|---|---|---|
| Surgery 手术 | 42537 – 42537 CNY | Pre-reimbursement 医保报销前 | Per-item price 项目价 | 2025 |
| Surgery 手术 | 12000 – 20000 CNY | Pre-reimbursement 医保报销前 | Per-item price 项目价 | 2025 |
| Organ procurement 器官获取 | 250000 – 250000 CNY | Self-pay 自费 | Per-item price 项目价 | 2025 |
3 cost ranges for this condition, each with its source on the row page.
Values written in Chinese are quoted as published by the source.
Outcomes and care quality
Liver transplant recipient outcome at 1 / 3 / 5 years: 83.7% / 74.5% / 68.9% (deceased donor) and 92.4% / 89.3% / 88.2% (living donor)
CLTR data, 2015-2021, quoted through the Chinese expert consensus on mTOR inhibitors in liver transplant recipients (2023 edition) - a secondary citation; the 2017 official release (84% / 75% / 71%) is a footnote.
- Chinese expert consensus on mTOR inhibitors in liver transplant recipients (2023 edition), citing CLTR 2015-2021
- National Health Commission press briefing, 2018 (2017 figures, via People's Daily)
Source retrieved 2026-10-01.
The figure is an official publication, quoted as published - it is not our assessment or our recommendation.
Hospitals with a published record for this condition
Selected using official public data sources
These hospitals are selected from official public data sources — the Fudan University hospital specialty reputation rankings, the national key clinical specialties list and national clinical research centres — so each line on a card can be checked against its published source. This is not a paid or promoted listing.
How these hospitals were selected
Admission. A hospital is listed for a condition when the specialty that condition is filed under carries at least one of: a place or a nomination in the Fudan University hospital specialty reputation ranking; a national key clinical specialty record at level A, B or C; or a national clinical research centre or a state key laboratory in that specialty. JCI accreditation is shown as a badge; it never decides admission and it never decides order.
Order. Step 1: a Fudan place between 1 and 10 for the specialty. Step 2: another Fudan place, or a nomination. Step 3: a level-A national key clinical specialty. Step 4: a level-B national key clinical specialty. Step 5: a national clinical research centre or a state key laboratory in the specialty, a centre before a laboratory. Step 6: a level-C national key clinical specialty, which is a record we publish without an independent official source and which is therefore listed after the others.
Ties. Within one step: the better Fudan place first, then the stronger key-specialty level (A before B before C), then the province, then the city, then the hospital name - the same province-city-name order the hospital directory uses. At most eight hospitals are listed.
When the list is short. Five hospitals or more: the first eight are listed. Three or four: all of them are listed, and a further fold adds the remaining records up to eight, each carrying its evidence level. One or two: the same, with that fold open and a line stating how many hospitals have a strong public record. None: the page states that no strong public record was found and links to the specialty directory. A place, an institution or a count is never invented to fill the list.
The Fudan rankings are the hospital specialty reputation ranking most widely recognised by Chinese clinicians, published annually by Fudan University's hospital management institute.
-
West China Hospital, Sichuan University四川大学华西医院
National key clinical specialty
- Organ Transplantation (level A) https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Also ranked: General Surgery #3, Thoracic Surgery #4, Urology #2 (tied) in the Fudan list.
-
Tianjin First Center Hospital天津市第一中心医院
National key clinical specialty
- Organ Transplantation (level A) https://www.tmu.edu.cn/yxy/1338/list.htm
-
The First Affiliated Hospital, Zhejiang University School of Medicine浙江大学医学院附属第一医院
National key clinical specialty
- Organ Transplantation (level A) http://zdygb.zju.edu.cn/2014/0106/c34026a1762975/page.htm
Also ranked: General Surgery #7, Urology #9, Infectious Diseases 传染感染 #2 in the Fudan list.
-
Shanghai Pulmonary Hospital上海市肺科医院
National key clinical specialty
- Organ Transplantation (level B) https://www.shsfkyy.com/gzb/list/b980f2cf4b134e5d85397ced965ce260/74344ed2746449a68d71c2b76c8cf423.html
Also ranked: Thoracic Surgery #3, Respiratory Medicine nominated in the Fudan list.
-
Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院
National key clinical specialty
- Hepatobiliary Surgery (level B) https://www.shca.org.cn/home/news/content/id/297/pid/25651
Also ranked: Thoracic Surgery #10, Medical Oncology #3, Nuclear Medicine 核医学 nominated in the Fudan list.
-
China-Japan Friendship Hospital中日友好医院
National key clinical specialty
- Hepatobiliary Surgery (level B) https://www.zryhyy.com.cn/zryh/c100020/202309/47e8245aa93343baac89762d4e80580f.shtml
Also ranked: Respiratory Medicine #2, Thoracic Surgery nominated in the Fudan list.
-
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital四川省医学科学院·四川省人民医院
National key clinical specialty
- Organ Transplantation (level B) https://www.samsph.com/news_hos/2023/xe7kw1e7.html
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University中山大学孙逸仙纪念医院
National key clinical specialty
- Organ Transplantation (level B) https://www.gzsys.org.cn/basic/453
Also ranked: Urology #4, General Surgery nominated, Gynecology nominated in the Fudan list.
Clinical trials (investigational treatments)
In addition to standard care, clinical research studies for Liver transplantation may currently be open to participants in China. The treatments under study have not been approved by the regulator as standard therapy — they are clinical research, not routine treatment. Each record names the lead investigator and the hospital running the study. If you are interested, contact the hospital to ask about eligibility and choose whether to apply.
-
Study Children's Hospital of Chongqing Medical University
- Lead investigator
- Qiu Li · dean
- Hospital
- Children's Hospital of Chongqing Medical University
- Status
- Recruiting
- Registry
- NCT04477967
-
Study A Prospective, Single-arm Study of Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation
- Hospital
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- Status
- Recruiting
- Registry
- NCT05475613
-
Study A Prospective, Single Arm, Exploratory Study of Using Drug-eluting Beads Transarterial Chemoembolization Prior to Liver Transplantation in the Treatment of Hepatocellular Carcinoma
- Lead investigator
- Kang He · Professor
- Hospital
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
- Status
- Recruiting
- Registry
- NCT06353126
-
Study A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation (ESTA Trial)
- Hospital
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
- Status
- Recruiting
- Registry
- NCT07157631
-
Study Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation
- Lead investigator
- Beicheng Sun · Director, Hepatobiliary Surgery
- Hospital
- Nanjing Drum Tower Hospital
- Status
- Recruiting
- Registry
- NCT04595864
2 more registered studies
-
Study The Effect of Donor-oriented Anti-infection Therapy Based on mNGS Etiological Diagnosis on the Incidence of Perioperative Infection and Prognosis of Corresponding Recipients After Liver Transplantation
- Lead investigator
- Pusen Wang · Principal Investigator
- Hospital
- Shenzhen Third People's Hospital
- Status
- Not yet recruiting
- Registry
- NCT06212115
-
Study A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Hepatocellular Carcinoma Beyond UCSF Criteria Before Liver Transplantation
- Lead investigator
- lucaide · Chief Physician/Professor
- Hospital
- Ningbo Medical Center Lihuili Hospital
- Status
- Not yet recruiting
- Registry
- NCT07310836
This page only shares publicly registered study information. It does not recommend or encourage joining any study. Participation is entirely voluntary and the risks of an unapproved treatment are unknown; contact the hospital directly for eligibility and informed-consent details.
Hospitals with a national key specialty record
Show the hospital records 17 hospitals with a key-specialty record
Each row is a hospital with a national key clinical specialty record in a specialty this condition is filed under. This is a record of published listings, not a recommendation and not a ranking.
17 hospitals with a matching national key specialty record.
Values written in Chinese are quoted as published by the source.
Questions about this condition
We cannot give medical advice, but we can answer questions about this page and about arranging treatment in China.
ICD codes
Show the code table 2 ICD codes
| Version | Code | Name in that version |
|---|---|---|
| ICD-10-WHO | Z94 | Transplanted organ and tissue status |
| ICD-10-WHO | Z94.4 | Liver transplant status |
Rows are the WHO ICD-10 entries for this condition, quoted as published.
Source & evidence
- Source URL
- https://www.nhsa.gov.cn/art/2024/11/18/art_201_14705.html
- Source scheme
- https
- Source type
- National Health Commission
- Evidence level
- A - said by a provincial health commission or university
- Retrieved on
- 2026-09-30